The Filing Desk

Anika Therapeutics vs Sanara MedTech

Anika Therapeutics ANIK · Sanara MedTech SMTI · Health Care Equipment

Anika Therapeutics reported revenue of $113 million in fiscal 2025, about the same as Sanara MedTech's $103 million in fiscal 2025. Anika Therapeutics' revenue fell 5.9% in its latest year, and Sanara MedTech's grew 19.0%. Anika Therapeutics had an operating margin of -9.8%, against 7.1% at Sanara MedTech. Free cash flow was $4 million at Anika Therapeutics and $2 million at Sanara MedTech.

Side by side

Anika TherapeuticsSanara MedTech
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$113M$103M
Revenue growth−5.9%19.0%
Revenue growth a year, last 5 years−2.9%45.9%
Gross margin56.6%92.7%
Operating margin−9.8%7.1%
Net margin−9.6%−36.4%
Free cash flow$4M$2M
Free cash flow margin3.9%2.1%
Return on capital—13.0%
Net debt to EBITDA—2.6x
Dividends and buybacks$10M$0M
Change in diluted share count−2.6%1.6%
Last close$13.28$32.67
P/E at the last close——
Insider trades, last 12 monthsbought $264,308, sold $0—
Piotroski F-score—3 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Anika TherapeuticsSanara MedTech
Operating margin
Percent of revenue
Anika TherapeuticsSanara MedTech
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Anika TherapeuticsSanara MedTech

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Anika Therapeutics and Sanara MedTech pages.